Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks
With the third quarter well underway and most second-quarter earnings now in the rearview mirror, investors are starting to look ahead to the rest ...
Biomea Fusion Inc. (BMEA)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,049,802 | $3,013,208 | +72% | 0% |
| 2. | Renaissance Technologies Jim Simons | 1,455,474 | $2,139,547 | +11% | 0% |
| 3. | 178,300 | $262,101 | -28% | 0% | |
| 4. | LMR Partners Ben Levine, Andrew Manuel And Stefan Renold | 200,000 | $261,000 | 0% | |
| 5. | Jain Global LLC Bobby Jain | 75,698 | $111,276 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.43 | 30,000 | $42,999.00 | 723,027 | 2025-12-11 | Filing | |
| $0.99 | 100,000 | $99,180.00 | 115,000 | 2025-12-02 | Filing | |
| $1.05 | 10,000 | $10,500.00 | 693,027 | 2025-12-01 | Filing | |
| $1.10 | 40,000 | $44,052.00 | 683,027 | 2025-11-28 | Filing | |
| $10.06 | 10,000 | $100,600.00 | 15,000 | 2024-09-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $34.56 | 50,000 | $1,728,165.00 | 3,500,000 | 2023-06-01 | Filing | |
| $33.81 | 75,000 | $2,535,750.00 | 3,550,000 | 2023-05-31 | Filing | |
| $33.84 | 25,000 | $846,000.00 | 3,625,000 | 2023-05-12 | Filing | |
| $34.50 | 150,000 | $5,175,720.00 | 3,650,000 | 2023-05-09 | Filing | |
| $33.99 | 100,000 | $3,399,310.00 | 3,800,000 | 2023-05-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,814,946 | $12,957,970 | 0% | |
| 2. | 2,829,927 | $4,159,993 | 0% | |
| 3. | 2,048,757 | $3,011,673 | 0.64% | |
| 4. | 888,600 | $1,306,242 | 0% | |
| 5. | 723,176 | $1,063,069 | 0.03% |
News See All
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results
As of March 19, 2026, almost 88% of covering analysts keep bullish ratings on the stock.
Top 10 Stocks Under $5 That Could Triple
At one end of the spectrum, until a few weeks ago, there was optimism about the broader market's performance this year.
Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target
In Q3 2025, Biomea announced that the company was shifting its strategy to focus on its two primary assets: icovamenib, a menin inhibitor for type 2 diabetes/T2D, and BMF-650, an oral GLP-1 receptor agonist...
9 Overlooked Growth Stocks to Buy
On January 12, Victoria Greene, Founding Partner and CIO at G Squared Private Wealth, joined CNBC to discuss her current market outlook, selecting 'Fundamentals' as her word of the day.
10 Best Diabetes Stocks To Buy Under $10
About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income nations. Every year, diabetes directly causes 1.5 million deaths on average.
10 Best Biotech Penny Stocks to Buy Now
In 2024, the healthcare industry has been doing well, encouraging investors to look into new and exciting opportunities.
Analysts on Wall Street Lower Ratings for These 10 Stocks
Amidst the anticipation surrounding pivotal economic indicators, European futures are on the ascent, signaling a cautious optimism among traders as they prepare for the release of crucial US inflation...
12 Most Shorted Stocks in 2024
Short-sellers may be annoying for corporations (and Redditors?), but investors usually find themselves thanking these companies for doing the often back-breaking and excruciating research that is required...
5 Most Shorted Stocks Right Now
Biomea Fusion, Inc. (NASDAQ:BMEA) is a biotechnology firm seeking to treat cancer and diabetes.
Hedge Fund Resource Center